Bahaa E. Elgendy, PhD

St. Louis College of Pharmacy (STLCOP)

The main focus of Dr. Elgendy’s research group is drug design and organic synthesis. He designs and synthesize novel small organic molecules as modulators of nuclear hormone receptors for the therapeutic treatment of cancer, fatty liver diseases, Alzheimer’s Disease, and Atherosclerosis. Also, he synthesizes complex and diverse molecules to combat multi-drug resistant bacteria and anti-viral agents against HCV and ZIKV and other microbes. Dr. Elgendy incorporates computational methods such as quantitative structure activity relationships, pharmacophore modeling, and virtual screening in his drug discovery pipeline to accelerate the process of drug discovery and optimization.